volume 3 | issue 3 | november 2013 http://www.kidney-international.org Official Journal of the International Society of Nephrology KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease KDIGO gratefully acknowledges the founding sponsor, National Kidney Foundation, and the following consortium of sponsors that make our initiatives possible: Abbott, Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-Myers Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole Food Company, Fresenius Medical Care, Genzyme, Hoffmann-LaRoche, International Society of Nephrology, JC Penney, Kyowa Hakko Kirin, NATCO The Organization for Transplant Professionals, National Kidney Foundation (NKF)-Board of Directors, Novartis, Pharmacosmos, PUMC Pharmaceutical, Robert and Jane Cizik Foundation, Shire, Takeda Pharmaceutical, Transwestern Commercial Services, Vifor Pharma, and Wyeth. Sponsorship Statement: KDIGO is supported by a consortium of sponsors and no funding is accepted for the development of specific guidelines. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Tables and Figures v KDIGO Board Members vi Reference Keys vii CKD Nomenclature viiii Conversion Factors ix Abbreviations and Acronyms x Notice Foreword Work Group Membership Abstract Summary of Recommendation Statements Introduction: The case for updating and context Chapter 1: Assessment of lipid status in adults with CKD Chapter 2: Pharmacological cholesterol-lowering treatment in adults Chapter 3: Assessment of lipid status in children with CKD Chapter 4: Pharmacological cholesterol-lowering treatment in children Chapter 5: Triglyceride-lowering treatment in adults Chapter 6: Triglyceride-lowering treatment in children Methods for Guideline Development Biographic and Disclosure Information Acknowledgments References http://www.kidney-international.org contents & 2013 KDIGO VOL 3 | ISSUE 3 | NOVEMBER 2013 This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE) www.publicationethics.org TABLES Table 1. Secondary causes of dyslipidemias Table 2. 